GlassScriptPhysician profile
Kandala Chary
NPI 1578521381
$1,917.68
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $239 · 2021: $366 · 2022: $360 · 2023: $455 · 2024: $67.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $520 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $520.30 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $511.82 | 2019-2023 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $318.55 | 2019-2023 | Farxiga |
| Amgen INC. | $194.94 | 2019-2022 | |
| Vifor Pharma, INC. | $172.82 | 2019-2023 | Korsuva, Veltassa |
| Aurinia Pharma U.S., INC. | $146.77 | 2021-2023 | Lupkynis |
| Glaxosmithkline, LLC. | $109.08 | 2020-2021 | |
| Bard Peripheral Vascular, INC. | $103.15 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $78.79 | 2022-2023 | |
| Ultragenyx Pharmaceutical INC. | $67.92 | 2024 | Crysvita |
| Travere Therapeutics, INC. | $62.78 | 2023 | |
| Akebia Therapeutics INC | $45.94 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $25.34 | 2022 | |
| Ardelyx, INC. | $20.21 | 2023 | Ibsrela |
| Daiichi Sankyo INC. | $16.84 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.79 | 2023 | Gattex |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $14.42 | 2022 | |
| Fresenius USA Marketing, INC. | $12.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kandala Chary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.